Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis

Dataset

Description

<p><b>Background</b>: A previous meta-analysis demonstrated that 3 of the new-generation BCR-ABL tyrosine kinase inhibitors (TKIs) (dasatinib, nilotinib and ponatinib) are associated with an increased risk of vascular occlusive events in patients with Ph+ chronic myeloid leukemia compared with imatinib. This meta-analysis of randomized controlled trials aims at assessing these risks separately.</p> <p><b>Methods</b>: The literature search was performed by two independent reviewers following the previous protocol (PROSPERO 2014:CRD42014014147). A random-effects model and a fixed-effect model were used according to the characteristics of the included studies. Peto odds ratios with 95%CI were computed.</p> <p><b>Results</b>: Overall, 4.78% of patients developed arterial occlusive events with new generation TKIs compared with 0.96% with imatinib. Ponatinib (OR<sub>PETO</sub>:3.26; 95%CI:1.12 to 9.50), nilotinib (OR<sub>PETO</sub>: 3.69; 95%CI:2.29 to 5.95) and dasatinib (OR<sub>PETO</sub>:3.32; 95%CI:1.37 to 8.01) are all associated with a higher risk of arterial occlusive events than imatinib. Venous occlusive events occur in 0.72% of patients treated with new generation TKIs and in 0.27% of imatinib-treated patients. Overall, a trend toward an increase of the rate of venous occlusive events with new-generation TKIs (OR<sub>PETO</sub>:2.17; 95%CI:0.90 to 5.25) was highlighted but stratifications by treatment gave nonsignificant results.</p> <p><b>Conclusions</b>: Vascular occlusive events associated with new-generation BCR-ABL TKIs are driven by arterial occlusive events.</p>
Date made available29 Nov 2016
PublisherFigshare

Research Output

  • Cite this

    Graux, C. (Contributor), Chatelain, C. (Contributor), Mullier, F. (Contributor), Haguet, H. (Contributor), DOGNE, J. (Contributor), Douxfils, J. (Contributor) (29 Nov 2016). Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis. Figshare. 10.6084/m9.figshare.4265168.v1